134872-23-4

Basic information

• Product Name: 2-bromo-5-methylthiopyridine
• Synonyms: 2-bromo-5-methylthiopyridine;2-bromo-5-(methylthio)pyridine(SALTDATA: FREE);5-Methylthio-2-bromopyridine
• CAS NO: 134872-23-4
• Molecular Formula: C₆H₆BrNS
• Molecular Weight: 204
• Mol File: 134872-23-4.mol

Chemical Properties

• Melting Point: 54-56℃
• Boiling Point: 274.631°C at 760 mmHg
• Flash Point: 119.893°C
• Appearance: /
• Density: 1.617g/cm³
• Vapor Pressure: 0.009mmHg at 25°C
• Refractive Index: 1.63
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 0.04±0.10(Predicted)
• CAS DataBase Reference: 2-bromo-5-methylthiopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-5-methylthiopyridine(134872-23-4)
• EPA Substance Registry System: 2-bromo-5-methylthiopyridine(134872-23-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 134872-23-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-5-methylthiopyridine is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into various drug molecules, contributing to the development of new medications.
Used in Agrochemical Industry:
In the agrochemical field, 2-bromo-5-methylthiopyridine is utilized as a building block for the creation of pesticides and other agrochemical products, enhancing their effectiveness and selectivity.
Used in Materials Science:
2-bromo-5-methylthiopyridine is employed as a component in the development of new materials, leveraging its chemical properties to improve material characteristics such as stability and reactivity.
Used as a Reagent in Organic Synthesis:
2-bromo-5-methylthiopyridine is used as a reagent to introduce its specific moiety into different organic molecules, facilitating the synthesis of complex organic compounds for research and industrial applications.
Used in Medicinal Research:
2-bromo-5-methylthiopyridine is also utilized in medicinal research as a versatile tool to participate in a range of chemical reactions, aiding in the discovery and optimization of potential therapeutic agents.

InChI:InChI=1/C6H6BrNS/c1-9-5-2-3-6(7)8-4-5/h2-4H,1H3

Upstream product

• 624-28-2 2,5-dibromopyridine 
• 624-92-0 Dimethyldisulphide 
• 109-72-8 n-butyllithium 
• 18794-33-7 3-methylsulfanylpyridine 

Downstream Products

• 343262-51-1 2-bromo-5-methanesulfonylpyridine 
• 611168-64-0 2-(tributylstannyl)-5-(methylthio)pyridine 
• 1193244-96-0 2-bromo-5-(S-methylsulfinyl)pyridine 
• 1093967-06-6 2-amino-5-(isopropylsulfonyl)-3-{[5-(methylthio)pyridin-2-yl]methoxy}benzonitrile 
• 667882-37-3 1-(5-methylsulfanyl-pyridin-2-yl)-ethanone 
• 343629-25-4 5-methylsulfonyl-2-[5-phenyl-3-difluoromethyl-1H-pyrazol-1-yl]pyridine 

Relevant articles and documents

In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)- 5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor

The synthesis of a novel canine COX-2 selective inhibitor, 2-(3-difluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, and its in vitro and in vivo profile are described. Pyrazole 8 demonstrated excellent potency and selectivity for canine COX-2

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment of diseases including heart ( e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease.

PCSK9 INHIBITORS AND METHODS OF USE THEREOF

The invention relates to a novel inhibitor pharmacophore of PCSK9 and heteroaryl compounds that bind the PCSK9 protein.

PCSK9 INHIBITORS AND METHODS OF USE THEREOF

The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.

NOVEL COMPOUNDS AS GPR119 AGONISTS

The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.

SUBSTITUTED PYRIDINONE DERIVATIVES AND METHODS FOR MANUFACTURING THE SAME

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and the compound-containing pharmaceutical composition for treating a metabolic disorder. Specifically, the disclosed compound is represented by [Formula 1]. The compound activates GPR119, and thus can be used for treating metabolic disorders, that is, diabetes mellitus, diabetes mellitus-related diseases, diabetes mellitus-related microvessel complications, diabetes mellitus-related large vessel complications, cardiovascular disorders, metabolic syndrome and its constituent diseases, obesity, and other diseases. In Formula 1, P1, P2, P3, P4, L1, R4, n4, X, Y, Z1 and Z2 are the same as defined above.

NOVEL PYRIDAZINE DERIVATIVES

The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is hydrogen, C1-C6alkyl, C1-C6haloalkyl or C3-C6cycloalkyl; R2 is an optionally substituted hereroaryl; R3 is an optionally substituted heteroaryl; and R4 is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, hydroxy or cyano; or an agrochemically usable salt form thereof.

Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors

The discovery of heteroaryl-phenyl-substituted pyrazole derivatives as canine selective COX-2 inhibitors is described. Structure-activity relationship (SAR) studies of this class of compounds led to the identification of compound 1 which demonstrated a ca

New efficient access to thieno[3,2-b]pyridine derivatives via regioselective lithiation of 3-methylthiopyridine

The synthesis of thieno[3,2-b]pyridines was achieved using a three-step process allowing the construction of the thiophenic ring with 17-34% overall yields. The key step was the regioselective lithiation-bromination of the 3-methylthiopyridine induced by

Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

Structure-activity relationship (SAR) studies of 2-[3-di(and tri)fluoromethyl-5-arylpyrazol-1-yl]-5-methanesulfonylpyridine derivatives for canine COX enzymes are described. This led to the identification of 12a as a lead candidate for further progression. The in vitro and in vivo activity of 12a for the canine COX-2 enzyme as well as its in vivo efficacy and pharmacokinetic properties in dog are highlighted.